Cue Biopharma, Inc. (CUE)
Health Care · Biotechnology · NASDAQ
Cue Biopharma is a clinical-stage developer of precision immunotherapies focused on selectively modulating the immune system to treat autoimmune, allergic, and inflammatory conditions.
What Cue Biopharma, Inc. does
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable therapeutics designed to modulate disease-specific T cells for the treatment of immunological, allergic, and autoimmune diseases. The company's proprietary Immuno-STAT platform engineer therapies that selectively target T cells in vivo, while its lead asset CUE-221 is a humanized anti-IgE monoclonal antibody in development for allergic conditions.
Recent developments
The company recently licensed CUE-221 from Ascendant Health Sciences, submitted an IND for CUE-221 in food allergy, and completed a $50 million private placement. Leadership changes include the appointment of Dr. Dominic Borie as Chief Medical Officer and James M. Ahlers as CFO.
From Cue Biopharma, Inc.'s filing of 2026-08-14.
Themes: autoimmune disease, allergic disease therapy, precision immunotherapy, T-cell modulation, Treg therapy
Fundamentals
- Price$17.04 as of 2026-10-20 close
- Market cap$124M as of 2026-08-12 (share count; price 2026-10-20)
- 1-year return-30.8% 2025-10-20 close $24.63 → 2026-10-20 close $17.04
- P/En/a negative earnings
- Net margin-96.9% FY2025, SEC XBRL
- ROE-100.6% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+195.8% FY2025, SEC XBRL
- Revenue CAGR (3y)+180.5% SEC XBRL
- Beta1.43 as of 2026-09-03
- Last reported earnings2026-08-14 SEC EDGAR Form 8-K (Item 2.02)
How CUE compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $8M | -$88M | -$153M | -$24.14 | -$29M† | $0† |
| Q1 FY2026 2026-03-31 | $6M | -$5M | -$5M | -$1.08 | -$11M | $121000 |
| Q4 FY2025 2025-12-31 | $22M† | $2M† | $2M† | $0.03† | -$1M† | $0† |
| Q3 FY2025 2025-09-30 | $2M | -$8M | -$7M | -$0.07 | -$9M† | $0† |
| Q2 FY2025 2025-06-30 | $3M | -$9M | -$8M | -$2.67 | -$3M† | $27000† |
| Q1 FY2025 2025-03-31 | $421000 | -$12M | -$12M | -$4.95 | -$8M | $150000 |
| Q4 FY2024 2024-12-31 | $2M† | -$10M† | -$9M† | -$0.10† | -$9M† | $2000† |
| Q3 FY2024 2024-09-30 | $3M | -$9M | -$9M | -$0.17 | -$8M† | -$1000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$17M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Cue Biopharma, Inc. looks technically
Cue Biopharma, Inc. (CUE) is trading 17.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 102 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 62.5% below its highest point of the past year. Trading volume is unusually light — only about 45% of its 30-day average.
Trend
7
| Distance from the 200-day | it is trading 17.7% below its 200-day average, the long-term trend line — a long-term downtrend | -17.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $26.95 | $26.95 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $20.70 | $20.70 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 102 trading days ago — a "golden cross", a bullish long-term signal | 102 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 18.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 35.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($15.93 to $29.00) — its "stochastic" reading is 9 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 8.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $45.50 | $45.50 |
|---|---|---|
| From the 52-week high | it is 62.5% below its 52-week high (its highest price of the past year) | -62.5% |
| Above the 52-week low | it is 242.2% above its 52-week low (its lowest price of the past year) | +242.2% |
| Below the 52-week high | it is 62.5% below its highest point of the past year | 62.5% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $950.70 (set on 2020-05-26) | $950.70 |
| Given back of the 52-week move | over the past year its closes ranged ($5.31 to $37.84), and it has given back close to two thirds of its rise from last year’s low — 64% of it. Chart-watchers call 61.8%-65% given back the "golden pocket", and this is inside it — for this company that is $16.70 to $17.74. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 63.9% |
| From the all-time high | it is 98.2% below its all-time high | -98.2% |
| Nearest price level | it is trading 6.1% below a resistance level at $18.08 — a price it turned at three times since 2025-05-21, most recently on 2026-05-21. Since 2024-10-21 it has 1 such level below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +6.1% |
| All-time low | its lowest closing price on record is $4.98 (set on 2026-04-06) | $4.98 |
| Above the all-time low | it is 242.2% above its all-time low | +242.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 75% of it) | 75th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.31 between its high and its low — about 19.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.31 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $14.10 and $33.59 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $14.10 – $23.85 – $33.59 |
| Typical daily range (% of price) | its price moves about 19.4% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 19.4% |
| Stretch from the 200-day average | it is trading 1.1 daily ranges below its 200-day average price (17.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 45% of its 30-day average | 0.45× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.6% |
|---|---|---|
| Gap filled | a 2.0% gap up opened on 2026-10-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 55.0 percentage points (the stock lost 54.0% while the market gained 1.0%) | -55.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 48.6 percentage points (the stock lost 44.9% while the market gained 3.6%) | -48.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 41.7 percentage points (the stock lost 33.2% while the market gained 8.5%) | -41.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 45.4 percentage points (the stock lost 30.8% while the market gained 14.6%) | -45.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 40% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 32.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -40.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 29% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $24.05 — a volume-weighted average of daily closes over 200 sessions, not a true tick-by-tick VWAP. | -29.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 39% below the average price paid since it last reported on 2026-08-14 (its 10-Q), so the typical buyer over that stretch is under water. That average is $27.88 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -38.9% |
Price levels it has turned at before
CUE last closed at $17.04 on 2026-10-20. Since 2024-10-21 it has turned at 1 price below its last close and 13 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $18.08 | Resistance | 6.1% above the last close | turned there three times · 2025-05-21 to 2026-05-21 |
| $22.68 | Resistance | 33.1% above the last close | turned there twice · 2025-08-13 to 2026-08-24 |
| $10.71 | Support | 37.2% below the last close | turned there twice · 2026-02-10 to 2026-04-28 |
| $24.67 | Resistance | 44.8% above the last close | turned there three times · 2025-11-13 to 2026-08-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$88.00 range $66.00 – $115.00; median $83.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["History of significant operating losses with no product revenue and a requirement for substantial additional capital to fund future operations.","Heavy reliance on the success of early-stage clinical candidates (CUE-221, CUE-401) which may fail or face regulatory hurdles.","Significant operational and financial volatility due to license agreements and one-time transaction-related charges."]
What changed in the latest 10-Q
AI-assisted comparison of CUE's 10-Q filed 2026-08-14 against the prior one filed 2026-05-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (filed 2026-08-14) states CUE-221 IND submission to the FDA has already occurred: 'We have recently submitted an Investigational New Drug, or IND, to the U.S. Food and Drug Administration, or FDA, to expand development into food allergy.'
- Older filing (filed 2026-05-14) described the CUE-221 IND as an expected future submission: 'We are expecting to submit an Investigational New Drug, or IND, amendment to the U.S. Food and Drug Administration, or FDA, to expand development into food allergy in the second half of 2026.'
- Removed:
- Newer filing (filed 2026-08-14) removed the statement that the CUE-221 IND submission would be in the second half of 2026.
- Newer filing (filed 2026-08-14) removed the phrase 'Events that Raise Substantial Doubt About Our Ability to Continue as a Going Concern' as a separate heading before the liquidity discussion.
- Reworded:
- Newer filing (filed 2026-08-14) changed 'We are expecting to submit an Investigational New Drug, or IND, amendment to the U.S. Food and Drug Administration, or FDA, to expand development into food allergy in the second half of 2026' to 'We have recently submitted an Investigational New Drug, or IND, to the U.S. Food and Drug Administration, or FDA, to expand development into food allergy.'
- Newer filing (filed 2026-08-14) changed the CUE-221 Phase 2 CSU clinical results timing from 'in the second half of 2026' to 'by the end of the third quarter of 2026.'
- Notes:
- The newer MD&A text appears truncated at 'Liquidity' section: it ends with 'During the three months ended June 30, 2026, we had one-time cash outflows related to t' and does not include the full liquidity/going concern narrative from the newer filing.
- The older MD&A text appears truncated within the going concern/liquidity section: it ends with 'Events that Raise Substantial Doubt About Our Ability to Continue as a Going Concern We have incurred significant losses since our inception and have never generated revenue or profit from product' and does not include the full liquidity/going concern narrative from the older filing.
- Because both texts are truncated in the liquidity/going concern area, any changes in that section beyond the heading removal may not be fully assessable from the provided excerpts.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 15 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 4 sells ($389304) — 3 selling insiders
- Last 90 days · read to 2026-10-160 buys · 15 sells ($2M) — 3 selling insiders
- Last 180 days · read to 2026-10-160 buys · 15 sells ($2M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-12. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CUE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding CUE as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 123,762
- Reported value $3,905,928
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CUE's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CUE had 702,198 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
CUE had 9.67% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.05 days to cover at the same settlement.
- Reported short interest (shares) 702,198
- Short interest (% of shares outstanding) 9.67%
- Prior settlement (shares) 332,105
- Reported change 111.44%
- Days to cover (reported) 1.05
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Regeneron Pharmaceuticals (REGN)
- Sanofi (SNY)
- Novartis (NVS)
- Amgen (AMGN)
- AstraZeneca (AZN)
- Boehringer Ingelheim
- ImmunoScape Pte. Ltd.
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CUE vs…
CUE shows up in…
Frequently asked questions
What does Cue Biopharma, Inc. (CUE) do?
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable therapeutics designed to modulate disease-specific T cells for the treatment of immunological, allergic, and autoimmune diseases. The company's proprietary Immuno-STAT platform engineer therapies that selectively target T cells in vivo, while its lead asset CUE-221 is a humanized anti-IgE monoclonal antibody in development for allergic conditions.
What sector is Cue Biopharma, Inc. (CUE) in?
Cue Biopharma, Inc. (CUE) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are Cue Biopharma, Inc.'s (CUE) competitors?
Notable peers of Cue Biopharma, Inc. (CUE) include Regeneron Pharmaceuticals, Sanofi, Novartis, Amgen and AstraZeneca. This peer set is informational only — not financial advice.
Is Cue Biopharma, Inc. (CUE) overbought or oversold right now?
Cue Biopharma, Inc. (CUE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CUE come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.